Perspective Therapeutics (CATX) Competitors $2.85 +0.01 (+0.35%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends CATX vs. LQDA, BVS, EYE, FNA, AVNS, BFLY, IRMD, AXGN, SMLR, and SIBNShould you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include Liquidia (LQDA), Bioventus (BVS), National Vision (EYE), Paragon 28 (FNA), Avanos Medical (AVNS), Butterfly Network (BFLY), Iradimed (IRMD), AxoGen (AXGN), Semler Scientific (SMLR), and SI-BONE (SIBN). These companies are all part of the "medical equipment" industry. Perspective Therapeutics vs. Liquidia Bioventus National Vision Paragon 28 Avanos Medical Butterfly Network Iradimed AxoGen Semler Scientific SI-BONE Perspective Therapeutics (NYSE:CATX) and Liquidia (NASDAQ:LQDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Do insiders and institutionals hold more shares of CATX or LQDA? 54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 3.5% of Perspective Therapeutics shares are owned by company insiders. Comparatively, 30.1% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation and earnings, CATX or LQDA? Perspective Therapeutics has higher earnings, but lower revenue than Liquidia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerspective Therapeutics$1.43M134.70-$46.51MN/AN/ALiquidia$15.61M60.18-$78.50M-$1.63-6.81 Do analysts rate CATX or LQDA? Perspective Therapeutics presently has a consensus target price of $15.14, indicating a potential upside of 431.33%. Liquidia has a consensus target price of $25.38, indicating a potential upside of 128.60%. Given Perspective Therapeutics' higher probable upside, equities research analysts clearly believe Perspective Therapeutics is more favorable than Liquidia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perspective Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Liquidia 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.11 Which has more volatility & risk, CATX or LQDA? Perspective Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Does the media prefer CATX or LQDA? In the previous week, Liquidia had 5 more articles in the media than Perspective Therapeutics. MarketBeat recorded 6 mentions for Liquidia and 1 mentions for Perspective Therapeutics. Perspective Therapeutics' average media sentiment score of 1.24 beat Liquidia's score of 0.74 indicating that Perspective Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perspective Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor CATX or LQDA? Liquidia received 183 more outperform votes than Perspective Therapeutics when rated by MarketBeat users. However, 94.74% of users gave Perspective Therapeutics an outperform vote while only 68.14% of users gave Liquidia an outperform vote. CompanyUnderperformOutperformPerspective TherapeuticsOutperform Votes1894.74% Underperform Votes15.26%LiquidiaOutperform Votes20168.14% Underperform Votes9431.86% Is CATX or LQDA more profitable? Liquidia has a net margin of -765.38% compared to Perspective Therapeutics' net margin of -4,096.66%. Perspective Therapeutics' return on equity of -27.40% beat Liquidia's return on equity.Company Net Margins Return on Equity Return on Assets Perspective Therapeutics-4,096.66% -27.40% -23.16% Liquidia -765.38%-163.21%-67.14% SummaryPerspective Therapeutics beats Liquidia on 9 of the 17 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office... I put all the details together for you here — but please hurry. Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CATX vs. The Competition Export to ExcelMetricPerspective TherapeuticsSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$192.63M$4.33B$5.10B$19.18BDividend YieldN/A41.46%4.90%3.58%P/E RatioN/A25.3791.0841.22Price / Sales134.7045.671,113.5117.58Price / CashN/A43.4642.2621.28Price / Book1.077.364.785.32Net Income-$46.51M$13.64M$119.77M$989.67M7 Day Performance-18.10%-2.82%-1.87%-3.45%1 Month Performance-5.32%0.54%11.46%-3.73%1 Year PerformanceN/A41.80%30.53%12.06% Perspective Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CATXPerspective Therapeutics3.3599 of 5 stars$2.85+0.4%$15.14+431.3%N/A$192.63M$1.43M0.00116Positive NewsHigh Trading VolumeLQDALiquidia3.421 of 5 stars$11.14+2.0%$24.00+115.4%+3.7%$942.86M$15.61M-6.7050Analyst ForecastNews CoveragePositive NewsBVSBioventus3.6125 of 5 stars$11.22+1.7%$16.00+42.6%+104.8%$910.56M$555.06M-18.081,200Analyst UpgradePositive NewsEYENational Vision3.0681 of 5 stars$11.54+1.1%$14.00+21.3%-41.2%$908.78M$2.13B-57.0513,998Analyst RevisionNews CoveragePositive NewsFNAParagon 283.0454 of 5 stars$10.67+2.4%$15.60+46.2%-17.7%$893.29M$245.00M-14.08343,000AVNSAvanos Medical3.4844 of 5 stars$17.82-0.8%N/A-27.4%$819.01M$673.30M52.853,771BFLYButterfly Network0.6702 of 5 stars$3.52+3.8%$3.00-14.8%+213.0%$749.98M$76.22M-7.37460Gap DownIRMDIradimed4.3863 of 5 stars$53.50+1.7%$60.00+12.1%+20.2%$677.85M$65.56M36.05110Positive NewsAXGNAxoGen0.9855 of 5 stars$14.46+2.1%$15.00+3.7%+125.0%$636.36M$180.86M-44.47426Positive NewsSMLRSemler Scientific1.3135 of 5 stars$74.46+10.9%N/A+44.1%$617.27M$68.18M35.2792Gap UpHigh Trading VolumeSIBNSI-BONE4.3046 of 5 stars$13.76+2.5%$23.00+67.2%-35.2%$577.09M$138.89M-14.59350Positive News Related Companies and Tools Related Companies LQDA Alternatives BVS Alternatives EYE Alternatives FNA Alternatives AVNS Alternatives BFLY Alternatives IRMD Alternatives AXGN Alternatives SMLR Alternatives SIBN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CATX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CATX Stock Alerts